Kaijie Pan

TL;DR: In this article, the real-world effectiveness of two doses of BNT162b2 against a range of SARS-CoV-2 outcomes and to evaluate the nationwide public-health impact following the widespread introduction of the vaccine was estimated.

TL;DR: In this article, the authors provided estimates of the number of SARS-CoV-2 infections and COVID-19-related admissions to hospital (i.e., hospitalisations) and deaths averted by the nationwide vaccination campaign.

TL;DR: In this paper , the authors evaluated the effectiveness of a third dose of BNT162b2 among adults in a large US integrated health system and found that three-dose VE (median follow-up 1·3 months [SD 0·6]) was 88% against infection and 97% (95-98) against hospitalization.

TL;DR: Reductions in effectiveness against SARS-CoV-2 infections over time are likely primarily due to waning rather than Delta escaping vaccine protection, even in the face of widespread dissemination of Delta.

TL;DR: In this article, the authors estimated BNT162b2 vaccine effectiveness against Beta infections in Israel, a country with high vaccine uptake, by comparing infection risk between unvaccinated and fully-vaccinated (≥7 days after the second dose) contacts, and between un vaccinatedinated and partially- vaccinated ( ≤ 7 days after a second dose).